Her2 Positive Breast Cancer Clinical Trials

ReadTheTrial indexes 8 studies for Her2 Positive Breast Cancer. The most common development stage is Phase 3 (5 trials). Each trial page translates ClinicalTrials.gov eligibility, outcomes, and design into patient-friendly language so you can compare options quickly.

8 clinical trials found for Her2 Positive Breast Cancer.

Pipeline by Phase

PhaseTrialsDistribution
Phase 3 5
63%
Phase 2 2
25%
Phase 1 1
13%

Trial Status Breakdown

Trials for Her2 Positive Breast Cancer

A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Postivie Breast Cancer, With or Without Central Nervous System Metastases

NCT07413939 · NOT YET RECRUITING · Phase 3

A Randomized Controlled Phase III Clinical Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

NCT07518173 · NOT YET RECRUITING · Phase 3

A Randomized, Open-label, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus TCbHP in Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression

NCT07043725 · RECRUITING · Phase 3

Phase 1 Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab / Trastuzumab in Patients With Metastatic HER2-Positive Breast Cancer

NCT05378464 · RECRUITING · Phase 1

A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)

NCT05132582 · ACTIVE NOT RECRUITING · Phase 3

20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)

NCT04569747 · ACTIVE NOT RECRUITING · Phase 2

A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer

NCT04539938 · COMPLETED · Phase 2

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)

NCT03975647 · ACTIVE NOT RECRUITING · Phase 3

Frequently Asked Questions

What clinical trials are available for Her2 Positive Breast Cancer?

There are 8 clinical trials listed for Her2 Positive Breast Cancer. These span various phases from early safety studies to post-approval monitoring. Browse the trial listings below for details.

How do I find recruiting Her2 Positive Breast Cancer trials?

Look for trials with "Recruiting" status in the listings below, or visit our recruiting page to filter by condition. Each trial page includes decoded eligibility criteria to help you determine if you qualify.

What phases are Her2 Positive Breast Cancer trials in?

Current Her2 Positive Breast Cancer trials are distributed across: Phase 3 (5), Phase 2 (2), Phase 1 (1).

Find More Trials